Puzo Michael J buys $9 Million stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Puzo Michael J scooped up 825 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 27, 2016. The investment management firm now holds a total of 79,754 shares of Johnson & Johnson which is valued at $9 Million.Johnson & Johnson makes up approximately 5.98% of Puzo Michael J’s portfolio.

Other Hedge Funds, Including , Gardiner Nancy B boosted its stake in JNJ in the latest quarter, The investment management firm added 545 additional shares and now holds a total of 8,220 shares of Johnson & Johnson which is valued at $929,353. Johnson & Johnson makes up approx 3.99% of Gardiner Nancy B’s portfolio.Forbes J M Co Llp boosted its stake in JNJ in the latest quarter, The investment management firm added 686 additional shares and now holds a total of 92,674 shares of Johnson & Johnson which is valued at $10.5 Million. Johnson & Johnson makes up approx 3.02% of Forbes J M Co Llp’s portfolio.Raymond James Associates boosted its stake in JNJ in the latest quarter, The investment management firm added 247,537 additional shares and now holds a total of 2,475,788 shares of Johnson & Johnson which is valued at $281.2 Million. Johnson & Johnson makes up approx 0.96% of Raymond James Associates’s portfolio.

Johnson & Johnson closed down -0.04 points or -0.03% at $115.73 with 64,17,404 shares getting traded on Tuesday. Post opening the session at $116.01, the shares hit an intraday low of $115.45 and an intraday high of $116.23 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.